Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients
Status:
Withdrawn
Trial end date:
2019-02-25
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety and efficacy of oral vancomycin in
patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation. The
primary endpoint is looking at the effect of the drug on liver function tests, an important
surrogate of PSC disease activity at 12 weeks on treatment. Secondary endpoints include a
decrease in liver function tests at 1 year, changes in bilirubin and adverse events.
Effective treatment at the onset of PSC recurrence may lead to decreases in disease
progression, recurrent liver failure, and repeat liver transplantation.